45.13USD+1.58%Mkt Cap: 4.14B USDP/E: —Last update: 2026-05-26
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap4.14B USD
Enterprise Value4.22B USD
Revenue (TTM)536.20M USD
Gross Profit480.39M USD
Net Income (TTM)-25.55M USD
Revenue/Share5.952 USD
Last Price45.13 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees497
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)8.94
PEG—
EV/EBITDA262.52
EV/Revenue7.88
P/S7.76
P/B41.89
EPS (TTM)-0.50
EPS (Forward)5.01
52W Range
13.8890% of range48.61
52W High48.61 USD
52W Low13.88 USD
Profitability
Gross Margin97.89%
Oper. Margin-29.02%
EBITDA Margin3.00%
Profit Margin-5.21%
ROE-22.25%
ROA-4.22%
Growth
Revenue Growth55.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF37.78M USD
CapEx (TTM)58.16M USD
FCF Margin-9.54%
FCF Yield-1.24%
Net Debt62.99M USD
Net Debt/EBITDA3.92
Balance Sheet
Debt/Equity2.86
Current Ratio3.13
Quick Ratio2.82
Book Value/Sh1.068 USD
Cash/Share2.846 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)53.57 USD
Target Range43.00 USD – 60.00 USD
# Analysts14
Ownership
Shares Out.92.99M
Float87.08M
Insiders0.76%
Institutions114.03%
Short Interest
Short Ratio5.4d
Short % Float19.99%
Short % Out.15.29%
Shares Short14.22M
Short (prev mo.)13.45M
Technical
SMA 5036.36 (+24.1%)
SMA 20030.72 (+46.9%)
Beta1.14
S&P 52W Chg28.31%
Avg Vol (30d)2.81M
Avg Vol (10d)1.97M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—